Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2014

Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
DEVICE

Vortx Rx - Histotripsy BPH Device

Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HistoSonics, Inc.

INDUSTRY

NCT01775488 - Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada) | Biotech Hunter | Biotech Hunter